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SHORT TERM OUTCOMES ASSOCIATED WITH A CHANGE IN REIMBURSEMENT
FOR DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE
Haley J, Rasu R
University of Missouri-Kansas City, Kansas City, MO, USA
OBJECTIVES: Deep Brain Stimulation (DBS) is a Parkinson’s disease (PD) treatment
that surgically implants vibrating probes in the brain to reduce symptoms. This
study examined whether patient characteristics, hospital characteristics, or out-
comes differ before and after a Center for Medicaid andMedicare Services National
Coverage Decision (NCD) for DBS in PD.METHODS: The Healthcare Cost and Utili-
zation Project (HCUP) National Inpatient Sample for the years 2002-2004 was used
for this analysis. HCUP is sponsored by the Agency for Healthcare Research and
Quality. This observational, cross-sectional study examined 12-months before and
after the 04/01/2003 NCD. Inpatient stays were identified using the PD ICD-9 code
and the DBS CPT code. Multivariate analyses tested whether discharge status or
length of stay (LOS) differed after the NCD. RESULTS: This study evaluated 460
inpatient stays for PD DBS. This population had a mean age of 63.19 (range, 32-87);
was 66.09% male; and 84.13% of surgeries were in large hospitals. In the post-
period, patients were more likely to live in the South (p0.0001); less likely to use a
large hospital (p0.0001); more likely to use hospitals doing fewer DBS procedures
(p0.001); and more likely to use physicians with fewer DBS procedures (p0001).
After adjusting for hospital and patient characteristics, multivariate analyses pre-
dicted that compared to the pre-period, discharge to a short/long term care facility
rather than homewas 3.671 timesmore likely to occur in the post-period [OR:3.671,
CI(1.178-1.441)]; and predicted that longer LOS would occur in the post-period (Co-
efficient0.3022, p0.0003). CONCLUSIONS: This analysis suggests that compared
to before the Medicare benefit expansion, the patient population after the expan-
sion experienced worse outcomes. Further research is needed to examine whether
these differences remain over time to inform Policymakers about how and why
outcomes may differ before and after a benefit expansion.
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GUIDELINES TO REPORT CLINICALLY RELEVANT INFORMATION ABOUT
POINT-OF-CARE INR DEVICE PERFORMANCE
Shermock KM1, Lavallee DM2, Streiff MB3
1The Johns Hopkins Medical Institutions, Baltimore, MD, USA, 2Center for Medical Technology
and Policy, Baltimore, MD, USA, 3The Johns Hopkins University School of Medicine, Baltimore,
MD, USA
OBJECTIVES: A revised ISO guideline was recently published that recommended
methods to be used during the device approval process and to assess the quality of
point-of-care INR measures. Point of care devices should lead clinicians to the
proper clinical decision – the same decision they would make using the clinically-
accepted standard laboratory measure. Our method was developed explicitly to
correspond with the clinical decision-making process. We assessed the relative
performance of the ISO methods and a method that we developed and validated.
METHODS: In a previous trial, patients provided two INR measures at the same
clinic visit: one by point-of-care device and the other by venous sample analyzed at
a clinical laboratory. The resultant clinical decisions from the INR measures were
directly measured in the previous trial and were used as a standard for this anal-
ysis. We compared the ability of the ISO and our methods to predict when INR
measures lead to identical or different clinical decisions. RESULTS: The Shermock
method was significantly better (82% of predictions correct) than the revised ISO
method (61% correct, p0.0001) at predicting when two INRmeasures lead to iden-
tical or different clinical decisions. Only 41% of decisions predicted to disagree by
the revised ISOmethod actually disagreed (Shermock’s method 64%); while only
51% of decisions that actually agreed were correctly predicted (Shermock’s method
83%).CONCLUSIONS: The Shermockmethod is superior in providing information
that clinicians and patients care most about regarding the quality of INRmeasures
used to guide clinical decisions. The FDA should incorporate Shermock’s method
into the device approval process. Local clinical laboratories should use the Sher-
mock method in quality assurance assessments. Other methods should not be
used unless they provide information that has clinical meaning and is valued by
end-users.
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A NATIONAL STUDY OF OUT-OF-POCKET EXPENDITURES FOR MAMMOGRAPHY
SCREENING
LeMasters T, Sambamoorthi U
West Virginia University, Morgantown, WV, USA
OBJECTIVES: To identify variations in screeningmammography expenditures, pri-
marily out-of-pocket and total expenditures of women in the U.S. 40 – 64 years of
age, and factors associated with variations. METHODS: Retrospective analysis of
data collected from the 2007 and 2008 Medical Expenditure Panel Survey. Sample
included 2,020 women 40 – 64 years of age who received one mammogram in the
year 2007 or 2008. Ordinary least squares regression to describe relationships be-
tween out-of-pocket expenditures, out-of-pocket expenditure as a percentage of
total mammogram expenditure, and total yearly out-of-pocket expenditure for all
health care services, and independent variables such as insurance status and type,
income, region of the U.S., and type of facility where a mammogramwas received.
RESULTS: The average out-of-pocket expenditure for a mammogram in 2007 or
2008 was $33, representing 14.1% of the total mammogram expenditure ($266).
Even after controlling demographic and health factors, insurance status and type,
income, region of the U.S., and type of facility remained significant predictors of
mammography expenditures. Women without insurance paid a greater percent-
age (31.0%) compared to thosewith private insurance (13.7%); womenwho received
their mammogram at an outpatient facility (18.0%) and resided in the Southern
region of the U.S. (16.5%) also paid a greater percentage. CONCLUSIONS: Large
variations in out-of-pocket expenditures were observed among women with and
without insurance, between insurance types, geographic regions of the U.S. and
types of facilities where mammograms were received. Higher financial burden of
mammography screening among subgroups of women may act as a barrier to
future mammography screening.
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OBJECTIVES: Several studies have examined the effects of intervention related to
health information technology like the Electronic Prescribing (eRx) system on hos-
pital medication safety. However, these studies had relatively small sample sizes
with highly variable results. The study objective is to perform meta-analyses sys-
tematically review and quantify the effects of intervention related to Electronic
Prescribing system on hospital medication safety. METHODS: MEDLINE, EMBASE,
and two other databases were searched from 1998 to 2010 for studies assessing the
usage of Electronic Prescribing in hospitals. Among 29 papers obtained using data
extraction, a total of 9 studies discussing pre and post (Time series study) utiliza-
tion of Electronic Prescribing were chosen to study their impact on the medication
safety of the patients. Out of the 9 studies, 6 studies involved inpatient settings and
the remaining 3 studies involved outpatient settings. In order to quantify the ef-
fects of Electronic Prescribing system on hospital medication safety, we used the
Meta analysis by STATA®SE version10. RESULTS: Overall, medication safety was
significantly improved in intervention group involving Electronic Prescribing sys-
tem (OR 1.97, p0.002) compared with control group utilizing handwriting sys-
tem. Specifically, medication safety in inpatient settings was significantly im-
proved in Electronic Prescribing system intervention group (OR 2.08, p0.01).
CONCLUSIONS: The usage of Electronic Prescribing allows entry and retrieval of
patient clinical information at the point of care, thereby enhancing delivery of
quality healthcare services and lowering delivery costs for those services.
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OBJECTIVES:Amini-Health TechnologyAssessment (mini-HTA) is a defined tool in
the form of a checklist designed to quickly advise evidence-based decision-making
for funding when medical devices are introduced or adapted. The purpose of this
study was to describe the existing structures and trends for mini-HTAs in the
Nordic countries. METHODS: A structured web-based search was performed to
identify and compile information from national, regional and local authorities and
agencies. The mini-HTA systems were assessed by comparing the different struc-
tures across the Nordic countries. RESULTS: Denmark has the most structured
process, which has been developed and refined since the early 1990s and is today
compulsory in some settings. The mini-HTA format is a national standardised
checklist of 3-5 pages based partly of a limited systematic review and concerning
the prerequisites for and consequences of the medical device covering four per-
spectives: device, patient, organisation and economics. Non-compliance with
these four perspectives may lead to rejection of the medical device for funding.
Four regional HTA units in Sweden have implemented, and other regions are de-
veloping, standardised processes for mini-HTAs with a structure resembling the
Danish format. The Finnish Managed Uptake of Medical Methods (MUFF) group
affirms the benefits of implementing a structured mini-HTA process. Until a Finn-
ish format is in place it has been proposed to use the Danish format for evaluating
medical devices. In Norway, experiences from reviews of other mini-HTA systems
are being used to establish a national process for assessing new medical devices.
CONCLUSIONS:Countries in theNordics have seen advantages of usingmini-HTAs
when time and resources are insufficient to execute a comprehensive HTA. Mini-
HTAs have important criteria and have facilitated a more standardised and quick
uptake process of medical devices in the Nordics and have given the industry new
market access possibilities.
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METHODOLOGICAL CONSIDERATIONS IN MODELING THE ECONOMIC VALUE
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BACKGROUND: Clinical evaluations of diagnostic tests focus primarily on the sen-
sitivity and specificity of a test relative to a gold standard. When assessing eco-
nomic value, however, payers want to know of those tested, what percent are
accurately diagnosed? Thus, economic analyses often require the model to begin
with the population tested and apply the positive and negative predictive values
(PPV/NPV) of the test to determine the number of false-positives (FP) and false-
negatives (FN). Although PPV and NPV are functions of the sensitivity and specific-
ity of a test, they are also functions of the underlying disease prevalence.
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